Co-Founder, CEO

Tommy co-founded Atropos in early 2018 because he was excited by the broad potential and applications of the science. Tommy has spent his career trying to promote better human health, first as a physician-scientist and then through technology as an investor in biotechnology and healthcare companies and as an entrepreneur. In his time as a VC, Tommy became acquainted with Atropos co-founder Andrew Koff’s seminal discoveries in senescence modulation. Prior to founding Atropos, Tommy joined Sofinnova Ventures in 2014 as a Senior Analyst, where he co-managed  the firm’s public biotech portfolio and greatly supported the firm’s successful private investments in innovative technologies, including Ascendis (long-acting protein delivery for rare diseases; ticker ASND), Amarin (new cardiovascular therapy; ticker AMRN), Audentes (AAV gene therapy for rare diseases; ticker BOLD), Seres Health (live microbiome therapy; ticker MCRB), Natera (non-invasive cell-free DNA for prenatal testing and liquid biopsy; ticker NTRA), and Checkmate (TLR agonists). In 2016 after less than two years as a VC, Tommy received honorable mention in the industry's Timmerman Report annual feature "12 VCs Who Matter But You've Never Read About." 

While at Sofinnova, Tommy also co-founded the firm’s therapeutics-focused hedge fund, where he was a member of the General Partner and served as Associate Portfolio Manager. Prior to 2014, Tommy did a stint as Principal and Analyst on the healthcare investment team at Jennison Associates, and covered biotech stocks on the sell-side at a number of investment banks (including Guggenheim, Jefferies, and Piper Jaffray), ultimately as a Director and Senior Biotech Analyst.

Tommy has been a lead author of a number of scientific publications and investigator in several grants. He trained in internal medicine and a cardiology fellowship in the New York-Presbyterian Hospital system. Tommy holds an MD and PhD in Molecular and Cellular Biology from the Tri-Institutional program of Cornell Medical College/ Memorial Sloan-Kettering Cancer Center/ Rockefeller University (through the NIH Medical Scientist Training Program). He graduated with a BA in Chemistry magna cum laude from Harvard University.


©2018 by Atropos Therapeutics Inc.. Proudly created with